Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatiana M Prowell

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|June 1, 2012
Pathological complete response and accelerated drug approval in early breast cancerTatiana M Prowell, Richard Pazdur
Journal of the National Cancer Institute|December 13, 2007
Extended adjuvant therapy for breast cancer--how much is enough?Tatiana M Prowell, Vered Stearns
ACP Journal Club|July 4, 2006
Disease-free survival was greater with letrozole than tamoxifen in postmenopausal women with early breast cancerTatiana M Prowell, Vered Stearns
Journal of the Advanced Practitioner in Oncology|June 4, 2021
Words Matter: Use of Respectful Language in OncologyLaura J Zitella, Tatiana M Prowell
The Oncologist|October 13, 2004
What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?Tatiana M Prowell, Nancy E Davidson
Seminars in Oncology|December 6, 2006
Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?Tatiana M Prowell, Deborah K Armstrong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Lipophilic statins merit additional study for breast cancer chemopreventionTatiana M Prowell, Vered Stearns, Bruce Trock
The New England Journal of Medicine|February 15, 2019
Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast CancerTatiana M Prowell, Julia A Beaver, Richard Pazdur
The New England Journal of Medicine|April 14, 2016
Seamless Oncology-Drug DevelopmentTatiana M Prowell, Marc R Theoret, Richard Pazdur
The Lancet. Oncology|March 6, 2020
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy - Authors' replyJennifer J Gao, Joyce Cheng, Julia A Beaver, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|June 1, 2012
Pathological complete response and accelerated drug approval in early breast cancerTatiana M Prowell, Richard Pazdur
Journal of the National Cancer Institute|December 13, 2007
Extended adjuvant therapy for breast cancer--how much is enough?Tatiana M Prowell, Vered Stearns
ACP Journal Club|July 4, 2006
Disease-free survival was greater with letrozole than tamoxifen in postmenopausal women with early breast cancerTatiana M Prowell, Vered Stearns
Journal of the Advanced Practitioner in Oncology|June 4, 2021
Words Matter: Use of Respectful Language in OncologyLaura J Zitella, Tatiana M Prowell
The Oncologist|October 13, 2004
What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?Tatiana M Prowell, Nancy E Davidson
Seminars in Oncology|December 6, 2006
Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?Tatiana M Prowell, Deborah K Armstrong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Lipophilic statins merit additional study for breast cancer chemopreventionTatiana M Prowell, Vered Stearns, Bruce Trock
The New England Journal of Medicine|February 15, 2019
Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast CancerTatiana M Prowell, Julia A Beaver, Richard Pazdur
The New England Journal of Medicine|April 14, 2016
Seamless Oncology-Drug DevelopmentTatiana M Prowell, Marc R Theoret, Richard Pazdur
The Lancet. Oncology|March 6, 2020
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy - Authors' replyJennifer J Gao, Joyce Cheng, Julia A Beaver, et al.
Pageof 3